• Treating Persistent DME: Comparison of 3 Anti-VEGF Drugs

    Written By: Lynda Seminara
    Selected By: Neil M. Bressler, MD, and Deputy Editors

    Bressler et al. analyzed data from a DRCR.net trial and found that persistent diabetic macular edema was more common with bevacizumab than aflibercept or ranibizumab at 24 weeks of treatment —and that chronic persistent diabetic macular edema was more likely to occur in eyes that received bevacizumab than in those that received aflibercept.